HUMA Humacyte, Inc.

NASDAQ
$0.56

Humacyte, Inc. (HUMA) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.09 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.4% since its last earnings release on August 12, 2026.

Humacyte Missed Consensus Estimates
Wednesday, August 12, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.09)
Rev est $860K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.61

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Humacyte, Inc.

Humacyte, Inc. is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.